Zacks Investment Research upgraded Kura Oncology, Inc. to a Rank #2 (Buy) on September 2, 2026. Rising earnings estimates prompted the positive shift in analyst sentiment.
The company is currently commercializing KOMZIFTI, an FDA-approved drug for acute myeloid leukemia. Analysts report growing confidence in the drug's market rollout and the company's broader pipeline.
Second-quarter results featured growing revenue alongside widening net losses. Kura Oncology will present at three healthcare investor conferences in September.